Homology Medicines Inc (NASDAQ:FIXX) Expected to Post Earnings of -$0.72 Per Share

Analysts expect Homology Medicines Inc (NASDAQ:FIXX) to report ($0.72) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Homology Medicines’ earnings, with estimates ranging from ($0.74) to ($0.69). Homology Medicines posted earnings per share of ($0.51) in the same quarter last year, which indicates a negative year-over-year growth rate of 41.2%. The company is scheduled to report its next quarterly earnings report on Tuesday, March 10th.

According to Zacks, analysts expect that Homology Medicines will report full year earnings of ($2.61) per share for the current financial year, with EPS estimates ranging from ($2.67) to ($2.50). For the next fiscal year, analysts forecast that the business will post earnings of ($2.95) per share, with EPS estimates ranging from ($3.21) to ($2.74). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Homology Medicines.

Several research analysts recently weighed in on FIXX shares. Robert W. Baird started coverage on Homology Medicines in a research report on Monday, September 9th. They issued an “outperform” rating and a $30.00 price objective for the company. FIX initiated coverage on Homology Medicines in a report on Thursday, October 31st. They set a “market perform” rating on the stock. HC Wainwright set a $36.00 price objective on Homology Medicines and gave the stock a “buy” rating in a report on Tuesday, September 24th. Oppenheimer began coverage on Homology Medicines in a report on Friday, November 1st. They set a “market perform” rating on the stock. Finally, ValuEngine lowered Homology Medicines from a “buy” rating to a “hold” rating in a report on Monday, November 25th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $31.40.

In other Homology Medicines news, CEO Arthur Tzianabos sold 12,500 shares of Homology Medicines stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $17.40, for a total value of $217,500.00. Also, insider Albert Seymour sold 9,300 shares of Homology Medicines stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $17.39, for a total transaction of $161,727.00. Insiders have sold a total of 83,400 shares of company stock valued at $1,380,749 over the last 90 days. Insiders own 33.40% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in FIXX. Aperio Group LLC bought a new position in Homology Medicines in the 2nd quarter worth about $34,000. Bank of Montreal Can bought a new stake in Homology Medicines in the 2nd quarter valued at $40,000. Cubist Systematic Strategies LLC bought a new stake in Homology Medicines in the 2nd quarter valued at $42,000. Marshall Wace LLP bought a new stake in Homology Medicines in the 1st quarter valued at $74,000. Finally, Royal Bank of Canada boosted its holdings in Homology Medicines by 300.0% in the 2nd quarter. Royal Bank of Canada now owns 4,000 shares of the company’s stock valued at $78,000 after purchasing an additional 3,000 shares during the period. 73.71% of the stock is owned by hedge funds and other institutional investors.

FIXX traded up $0.56 during trading hours on Friday, hitting $20.71. The stock had a trading volume of 206,118 shares, compared to its average volume of 372,791. The company’s fifty day simple moving average is $14.75 and its 200 day simple moving average is $17.44. Homology Medicines has a 1 year low of $11.05 and a 1 year high of $31.80. The stock has a market cap of $887.30 million, a PE ratio of -10.36 and a beta of 0.15.

About Homology Medicines

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Recommended Story: Basic Economics creates winners and losers

Get a free copy of the Zacks research report on Homology Medicines (FIXX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Homology Medicines (NASDAQ:FIXX)

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.